Cargando…
Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series
Our case series showed that eculizumab is efficacious and safe in treating thrombotic microangiopathy, as well as it has positive effects on quality of life. Further extensive studies are required to develop unified treatment guidelines.
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922540/ https://www.ncbi.nlm.nih.gov/pubmed/35317070 http://dx.doi.org/10.1002/ccr3.5573 |